Pacira BioSciencesFRA:82P +2.75%75 Days Payable is 36.30 as of Mar. 2026, which is 1% below its 10-year median of 36.72. GuruFocus rates FRA:82P with a GF Score™ of 75/100 and a GF Value™ of €25.72. The stock has 8 warning signs investors should review. Among 922 Drug Manufacturers companies, Pacira BioSciences ranks worse than 76.46% on this metric.
The historical rank and industry rank for Pacira BioSciences's Days Payable or its related term are showing as below:
FRA:82P'
s Days Payable Range Over the Past 10 Years
Min: 23.59 Med: 36.72 Max: 61
Current: 48.14
During the past 13 years, Pacira BioSciences's highest Days Payable was 61.00. The lowest was 23.59. And the median was 36.72.
FRA:82P's Days Payable is ranked worse than 76.46% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs FRA:82P: 48.14
Pacira BioSciences's Days Payable
declined
from Mar. 2025 (57.09) to Mar. 2026 (36.30).
It may suggest that Pacira BioSciencesaccelerated paying its suppliers.
Pacira BioSciences Days Payable Related Terms
Pacira BioSciences Days Payable Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:82P vs ETON, AMPH, BIOA: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pacira BioSciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (FRA:82P) has a Days Payable of 36.30 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pacira BioSciences and its competitors. This is near median its historical median of 36.72. Over the past decade, Pacira BioSciences' Days Payable has ranged from 23.59 to 61.00. According to the industry distribution chart, Pacira BioSciences ranks #705 out of 922 companies in the Drug Manufacturers industry, placing it in the top 76.5%.
Is Pacira BioSciences' Days Payable too high?
Pacira BioSciences' current Days Payable of 36.30 is near median its 10-year median of 36.72. Over the past 10 years, this metric has ranged from a low of 23.59 to a high of 61.00. The Drug Manufacturers industry median Days Payable is 90.61. Pacira BioSciences' value of 36.30 is 59.9% below this industry median. Based on the distribution chart, Pacira BioSciences ranks #705 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pacira BioSciences has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Days Payable compare to ETON and AMPH?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #705 out of 922 companies for Days Payable. This places Pacira BioSciences in the lower half of its industry. The industry median Days Payable is 90.61. Pacira BioSciences' value of 36.30 is 59.9% below this benchmark. Historically, Pacira BioSciences' own Days Payable has ranged from 23.59 to 61.00 over the past decade. While the company's 10-year median is 36.72 vs. the industry median of 90.61, Pacira BioSciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current Days Payable of 36.30 is 59.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current Days Payable is 36.30, which is near median its own 10-year median of 36.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Days Payable of 36.30. The stock's GF Value™ is €25.72, compared to a current price of €22.40 — trading 12.9% below its estimated fair value. The current Days Payable is 36.30, which is near median its 10-year median of 36.72 and 59.9% below the Drug Manufacturers industry median of 90.61. Pacira BioSciences' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Days Payable is 36.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €22.40 is trading 12.9% below its estimated GF Value™ of €25.72.
Key valuation signals for FRA:82P:
Days Payable: 36.30 (near median its 10-year median of 36.72)
GF Value™: €25.72 vs. price of €22.40 (12.9% below fair value)
Industry Position: 59.9% below the Drug Manufacturers median (#705 of 922)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
75GF Score
Get the complete analysis for FRA:82P
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
